You are here: Industry Insights > CD137

News List

Innovent Publishes the Preclinical Results of IBI319 (Anti PD-1/CD137 Bispecific Antibody) in Nature Communications prnasia
November 08, 2021
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer...
Innovent Announces the First Patient Dosed in the Phase 1 Study of IBI319 (Anti-PD-1/CD137 Bispecific Antibody) in Patients with Advanced Malignant Tumors prnasia
July 16, 2021
Innovent Biologics, Inc. announced that the first patient has been dosed in a Phase 1a/1b study of IBI319, an anti-PD-1/CD137 bispecific antibody.
F-star Therapeutics Announces First Patient Dosed in FS120 Trial americanpharmaceuticalreview
December 24, 2020
F-star Therapeutics has announced the first patient has been dosed in its Phase 1 trial evaluating FS120, a first-in-class dual-agonist tetravalent bispecific antibody targeting CD137 (4-1BB, TNFRSF9) and OX40 (CD134, TNFRSF4).
Gilead and Agenus sign cancer drug development deal pharmaceutical-technology
January 03, 2019
Gilead Sciences has partnered with US-based biotechnology company Agenus for the development and commercialisation of up to five immuno-oncology (I-O) treatments.